Compassionate Use of LA Cabotegravir Plus Rilpivirine for People living with HIV-1 in Need of Parenteral Antiretroviral Therapy


Most people living with HIV-1 had advanced disease and achieved (16/28) or maintained (6/7) virological suppression with long-acting (LA) therapy. Cabotegravir LA + rilpivirine LA as compassionate use provided a valuable treatment option for individuals with adherence issues with oral therapy and advanced disease.